The shares of ImmunoGen, Inc. have increased by more than 61.31% this year alone. The shares recently went down by -1.52% or -$0.16 and now trades at $10.34. The shares of Biocept, Inc. (NASDAQ:BIOC), has slumped by -68.54% year to date as of 07/12/2018. The shares currently trade at $6.55 and have been able to report a change of 24.76% over the past one week.
The stock of ImmunoGen, Inc. and Biocept, Inc. were two of the most active stocks on Thursday. Investors seem to be very interested in what happens to the stocks of these two companies but do investors favor one over the other? We will analyze the growth, profitability, risk, valuation, and insider trends of both companies and see which one investors prefer.Profitability and Returns
Growth alone cannot be used to see if the company will be valuable. Shareholders will be the losers if a company invest in ventures that aren’t profitable enough to support upbeat growth. In order for us to accurately measure profitability and return, we will be using the EBITDA margin and Return on Investment (ROI), which balances the difference in capital structure. The ROI of IMGN is 371.00% while that of BIOC is -452.70%. These figures suggest that IMGN ventures generate a higher ROI than that of BIOC.Cash Flow
The value of a stock is ultimately determined by the amount of cash flow that the investors have available. Over the last 12 months, IMGN’s free cash flow per share is a negative -0.04.Liquidity and Financial Risk
The ability of a company to meet up with its short-term obligations and be able to clear its longer-term debts is measured using Liquidity and leverage ratios. The current ratio for IMGN is 3.70 and that of BIOC is 2.40. This implies that it is easier for IMGN to cover its immediate obligations over the next 12 months than BIOC.Valuation
IMGN currently trades at a P/S of 13.07 while BIOC trades at a P/B of 43.67, and a P/S of 123.03. This means that looking at the earnings, book values and sales basis, IMGN is the cheaper one. It is very obvious that earnings are the most important factors to investors, thus analysts are most likely to place their bet on the P/E.Analyst Price Targets and Opinions
The mistake some people make is that they think a cheap stock has more value to it. In order to know the value of a stock, there is need to compare its current price to its likely trading price in the future. The price of IMGN is currently at a -28.69% to its one-year price target of 14.50.
When looking at the investment recommendation on say a scale of 1 to 5 (1 being a strong buy, 3 a hold, and 5 a sell), IMGN is given a 2.00 while 2.50 placed for BIOC. This means that analysts are more bullish on the outlook for BIOC stocks.Insider Activity and Investor Sentiment
Short interest or otherwise called the percentage of a stock’s tradable shares currently being shorted is another data that investors use to get a handle on sentiment. The short ratio for IMGN is 4.87 while that of BIOC is just 47.37. This means that analysts are more bullish on the forecast for IMGN stock.
The stock of Biocept, Inc. defeats that of ImmunoGen, Inc. when the two are compared, with BIOC taking 4 out of the total factors that were been considered. BIOC happens to be more profitable, generates a higher ROI, has higher cash flow per share, higher liquidity and has a lower financial risk. When looking at the stock valuation, BIOC is the cheaper one on an earnings, book value and sales basis. Finally, the sentiment signal for BIOC is better on when it is viewed on short interest.